OTCMKTS:IMUN Immune Therapeutics (IMUN) Stock Price, News & Analysis $0.09 0.00 (0.00%) As of 10/19/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Immune Therapeutics Stock (OTCMKTS:IMUN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immune Therapeutics alerts:Sign Up Key Stats Today's Range$0.09▼$0.0950-Day Range$0.09▼$0.0952-Week Range$0.07▼$1.30Volume12 shsAverage Volume15,246 shsMarket Capitalization$7.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewImmune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.Read More… Receive IMUN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUN Stock News HeadlinesSMART and KKH Develop First-of-Its-Kind Device (BLIPI) to Profile Newborns’ Immune FunctionMay 29, 2025 | msn.com9 Foods That Naturally Strengthen Your Immune SystemMay 25, 2025 | msn.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.June 12, 2025 | Brownstone Research (Ad)Lung Cancer Remains At Bay Long After Immune Therapy Is DroppedApril 21, 2025 | msn.comImmune Repertoire Sequencing Market worth US$560.5 million by 2030 with 9.6% CAGR | MarketsandMarketsApril 17, 2025 | finanznachrichten.de'Time machine' enzyme could improve mRNA-based therapeuticsApril 17, 2025 | msn.comRecently Discovered Immune Cell Type Is Key to Understanding Food AllergiesApril 14, 2025 | finance.yahoo.comPotential Alzheimer's disease therapeutic target identified in brain immune cellsApril 9, 2025 | msn.comSee More Headlines IMUN Stock Analysis - Frequently Asked Questions How have IMUN shares performed this year? Immune Therapeutics' stock was trading at $0.0930 on January 1st, 2025. Since then, IMUN shares have increased by 0.0% and is now trading at $0.0930. View the best growth stocks for 2025 here. How do I buy shares of Immune Therapeutics? Shares of IMUN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immune Therapeutics investors own include Asia Broadband (AABB), CRISPR Therapeutics (CRSP), Edge Therapeutics (EDGE), Gilead Sciences (GILD), Northwest Biotherapeutics (NWBO), Galiano Gold (AKG) and Agritek (AGTK). Company Calendar Today6/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:IMUN CIK1559356 Webwww.immunetherapeutics.com Phone(888) 613-8802FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.54 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-544.75% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-3.10Miscellaneous Outstanding Shares83,660,000Free Float41,335,000Market Cap$7.78 million OptionableNot Optionable Beta0.46 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:IMUN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersElon’s final win for Social Security?Elon's Successor? Elon Musk and President Trump's new feud is all over the news... but before he left Washi...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
